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Abstract
Background: Circulating endothelial cells (CEC) and endothelial precursor cells (CEP) have been
suggested as markers for angiogenesis in cancer. However, CEC/CEP represent a tiny and
heterogeneous cell population, rendering a standardized monitoring in peripheral blood difficult.
Thus, we investigated whether a PCR-based detection method of CEC/CEP might overcome the
limitations of rare-event flow cytometry.
Findings: To test the sensitivity of both assays endothelial colony forming cell clones (ECFC) and
cord blood derived CD45- CD34+ progenitor cells were spiked into peripheral blood mononuclear
cells (PBMNC) of healthy volunteers. Samples were analyzed for the expression of CD45, CD31,
CD34, KDR or CD133 by 4-color flow cytometry and for the expression of CD34, CD133, KDR
and CD144 by qPCR. Applying flow cytometry, spiked ECFC and progenitor cells were detectable
at frequencies ≥ 0.01%, whereas by qPCR a detection limit of 0.001% was achievable. Furthermore,
PBMNC from healthy controls (n = 30), patients with locally advanced rectal cancer (n = 20) and
metastatic non-small cell lung cancer (NSCLC, n = 25) were analyzed. No increase of CEC/CEP
was detectable by flow cytometry. Furthermore, only CD34 and KDR gene expression was
significantly elevated in patients with metastatic NSCLC. However, both markers are not specific
for endothelial cells.
Conclusion: QPCR is more sensitive, but less specific than 4-channel flow cytometry for the
detection of CEC/CEP cell types. However, both methods failed to reliably detect an increase of
CEC/CEP in tumor patients. Thus, more specific CEC/CEP markers are needed to validate and
improve the detection of these rare cell types by PCR-based assays.
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Findings
CEC a heterogenous and rare cell type of the peripheral 
blood
CEC have been shown to contribute significantly to ang-
iogenesis in ischemia, inflammation, wound healing and
tumor progression [1]. In cancer patients CEC measure-
ment in peripheral blood has been proposed a non-inva-
sive tool to assess tumor angiogenesis [2] and monitor
antiangiogenic therapies [3] CEC comprise a heteroge-
nous cell population consisting of endothelial cells shed
from the vessel wall [4], bone marrow-derived CEP [5]
and endothelial precursors originating from monocytic
cells [6] (figure 1). CEC are only a tiny subset of the
mononuclear cell fraction of peripheral blood rendering
their quantification a challenging task. Endothelial colony
formation assays are labor-intensive, time-consuming,
poorly standardised and may give rise preferentially to
monocytic cells [7]. Currently, the most common tech-
nique applied for CEC quantification is multicolor flow
cytometry. Based on this method absolute numbers of
CEC reported in the literature vary greatly ranging from 0
to 7.900 CEC/mL in peripheral blood of healthy controls
and from 5 to 39.000 CEC/mL under pathological condi-
tions [2,8]. Thus, there is an urgent need for more reliable
and standardized methods for CEC quantification.
In this study both methods, flow cytometry and qPCR,
were evaluated to compare the ability to detect mature
peripheral blood-derived endothelial colony forming
cells (ECFC; CEC phenotype) and cord blood-derived
progenitors (CEP phenotype) spiked into PBMNC of
healthy volunteers.
Phenotype analysis of cord blood progenitor cells and 
ECFC by flow cytometry
At first, the phenotypes of cord blood derived progenitor
cells and ECFC was determined by flow cytometry (figure
2). As expected, ECFC were CD45- CD31+ (figure 2A). Fur-
ther subtyping revealed that cells were CD34-KDR+. More-
over, cells were CD133- and CD144+ (data not shown).
Hypothetical model of the origin and immunophenotypic characteristics of distinct subpopulations of circulating endothelial  cells in peripheral blood Figure 1
Hypothetical model of the origin and immunophenotypic characteristics of distinct subpopulations of circulat-
ing endothelial cells in peripheral blood. Pluripotent stem cells reside in the stem cell niche of the bone marrow and can 
give rise to "hemangioblasts" that have the capacity to differentiate into hematopoietic progenitor cells (HPC) or endothelial 
progenitors (EPC). EPC differentiate into circulating endothelial precursors (CEP) and circulating endothelial cells (CEC). HPC 
differentiate into myeloid cells such as monocytes, that can transdifferentiate into myeloid EC. Moreover, mature EC shed 
from the vessel wall can enter the circulation. Various subsets of circulating endothelial cell types have been demonstrated to 
contribute to tumor angiogenesis.BMC Research Notes 2008, 1:71 http://www.biomedcentral.com/1756-0500/1/2
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Due to the two-step isolation procedure cord blood pro-
genitor cells displayed a CD45-/low CD34+ phenotype (fig-
ure 2B). The majority of CD34+ cells displayed a CD31+
CD133- phenotype corresponding to hematopoietic pre-
cursor cells. In accordance with previous reports only a
small subset of cells displayed a CD31+ CD133low pheno-
type (5–10% of the CD34+ cells)[9]. Therefore, only few
cord blood-derived progenitor cells were detectable in the
CEP window during the subsequent spiking experiments.
Moreover, progenitor cells were KDR- and CD144- (data
not shown).
Four-color flow cytometric analyses of endothelial cells within human mononuclear cells Figure 2
Four-color flow cytometric analyses of endothelial cells within human mononuclear cells. A) Staining for CD31, 
CD34, CD45 and KDR of PBMNC allows the detection of mature circulating endothelial cells. Top row: PBMNC sample of a 
healthy donor; lower row: autologous ECFC spiked into PBMNC from the respective healthy donor. B Staining for CD31, 
CD34, CD45 and CD133 of PBMNC allows the detection of circulating endothelial and progenitor cells. Top row: PBMNC 
sample of a healthy donor; lower row: cord-blood derived progenitors spiked into PBMNC from a healthy donor. Of note, 
only a small subset of cells displayed a CD34+ CD133 phenotype.BMC Research Notes 2008, 1:71 http://www.biomedcentral.com/1756-0500/1/2
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Detection of progenitors spiked into peripheral blood 
samples
In five independent experiments cord blood derived pro-
genitors from different donors were spiked in triplicates
into PBMNC from healthy volunteers at concentrations
ranging from 0.001 to 1%. As depicted in figure 3A, flow
cytometry allowed detection of progenitors with a CEP
phenotype at concentrations ≥ 0.01% (mean: 4 cells/106
PBMNC vs 1 cell in unspiked controls, p = 0.017).
Quantification of both CD34 and CD133 gene transcripts
proved to be a reliable approach for detecting spiked pro-
genitor cells in PBMNC samples with 10-fold greater sen-
sitivity than flow cytometry. At a frequency of only
0.001% progenitor cells were detectable by a 3.9-fold
increased gene expression for CD133 (SD 2.2) and a 3.4-
fold increase for CD34 (SD 2.3) in comparison to
unspiked controls (p = 0.03; figure 3B). Although linear,
the increase of CD34 and CD133 gene transcripts was not
proportional to the number of cells spiked, possibly due
to technical reasons (e.g., cell clumping) or cell death as
progenitor cells are more fragile compared to mature cells.
Due to their low expression on progenitors as described
above, CD144 and KDR gene expression was not ana-
lyzed.
Detection of ECFC spiked into peripheral blood samples
In five independent experiments freshly detached autolo-
gous ECFC were spiked into PBMNC samples of the
respective donor at concentrations ranging from 0.001 to
1%. Using flow cytometry ECFC spiked into PBMNC sam-
ples were detectable at frequencies ≥ 0.01% (mean: 68
cells/106 PBMNC vs 20 cells in unspiked controls, p =
0.004; figure 4A).
QPCR was at least 10-fold more sensitive than flow
cytometry for ECFC detection. Indeed, at a frequency of
0.001% relative gene expression of KDR was increased
48.3-fold (SD 52.1; p = 0.027) and that of CD144 40.8-
fold (SD 58.5; p = 0.04) compared to unspiked controls
(figure 4B). Due to their low expression level on ECFC as
described above, CD34 and CD133 gene transcripts were
not determined in this setting.
Detection of CEC/CEP in peripheral blood of cancer 
patients and healthy volunteers
Applying 4-color flow cytometry no significant differences
concerning CEC/CEP numbers were found between can-
cer patients and age-matched healthy controls (figure 5A).
We then applied qPCR for quantifying gene transcripts of
endothelial progenitor cell markers CD34, CD133 and
endothelial cell markers KDR and CD144. Overall, gene
transcripts for CD34 and CD144 were found abundantly
expressed (i.e., >100 copies/μg RNA) in the total study
cohort whereas only very few KDR or CD133 gene tran-
scripts were detectable (figure 5B). Subgroup analysis
showed no influence of gender, age or tumor stage on any
of the markers studied. No significant elevation of any of
the endothelial marker gene transcripts determined was
found in locally advanced rectal cancer patients. In con-
trast, in the cohort of patients with metastatic NSCLC a
significantly increased CD34 and KDR gene expression
was found (p = 0.028 and p = 0.002, respectively).
Discussion
Recently, CEC and CEP have been suggested as surrogate
markers for angiogenesis and response to antiangiogenic
therapy in cancer [10]. Flow cytometric rare event analy-
sis, currently the most commonly applied method for
CEC/CEP assessment, is technically demanding due to a
high level of "background noise", i.e. false positive events
due to autofluorescence, cell clumps and non-specific
Detection of progenitor cells spiked into peripheral blood  samples Figure 3
Detection of progenitor cells spiked into peripheral 
blood samples. A) Four-channel flow cytometric analysis of 
cord blood derived progenitor cells spiked into PBMNC (n = 
5). Progenitors were spiked at frequencies ranging from 
0.001 to 1% into PBMNC of a healthy donor. (* p < 0.05 
compared to unspiked controls). B) Quantitative PCR analy-
sis of CEP marker gene expression in peripheral blood sam-
ples containing cord blood derived progenitor cells spiked at 
varying frequencies (0.001–1%; five independent experi-
ments). Expression of CD34 and CD133 was analyzed in all 
samples relative to unspiked PBMNC. (* p < 0.05 compared 
to unspiked controls).BMC Research Notes 2008, 1:71 http://www.biomedcentral.com/1756-0500/1/2
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staining of other cell types such as monocytes, lym-
phocytes, non-lysed erythrocytes, aggregated platelets
[11], dead cells or endothelial microparticles. Further-
more, technical aspects such as inadequate cleaning of the
cytometer, blocking, washing and lysing procedures may
impact the flow-cytometric analysis. Even with freshly
drawn blood and standardized technical workup non-spe-
cific binding of fluorochrome-matched isotype controls
may be observed in up to 0.5% of cells analyzed markedly
exceeding the anticipated number of CEC and CEP within
the PBMNC fraction (0.01% to 0.0001%) [12]. As a result,
CEC/CEP measurements are virtually not comparable
between different laboratories posing a major obstacle for
the interpretation of the data published in the literature.
The detection limit of 0.001% CEC/CEP in PBMNC deter-
mined for qPCR in our spiking experiments is compatible
with frequencies of CEC/CEP in humans reported in the
literature [1] and well above the values determined by 4-
color flow cytometry (i.e., 0.01%).
However, despite markedly improved sensitivity deter-
mined in our spiking experiments we found normal
endothelial marker gene expression when we applied
qPCR to samples from patients with newly diagnosed
locally advanced rectal cancer. This may be due to the
rather low tumor burden in this study cohort as overall
angiogenic activity depends not only on the tumor type
but also on tumor load. When we analysed blood samples
Detection of ECFC in peripheral blood samples Figure 4
Detection of ECFC in peripheral blood samples. A) 
Four-channel flow cytometric analysis of autologous ECFC 
spiked into PBMNC of the respective donor (n = 5). ECFC 
were spiked at frequencies ranging from 0.001 to 1%. (* p < 
0.05 compared to unspiked controls). B) Quantitative PCR 
analysis of ECFC marker gene expression in peripheral blood 
samples containing ECFC spiked at varying frequencies 
(0.001–1%; five independent experiments involving five differ-
ent healthy donors). Expression of KDR and CD144 was ana-
lyzed in all samples relative to unspiked PBMNC. (* p < 0.05 
compared to unspiked controls).
Quantification of CEC and CEP in cancer patients and  healthy controls Figure 5
Quantification of CEC and CEP in cancer patients 
and healthy controls. The content of CEC and CEP was 
determined by flow cytometry and qPCR in peripheral blood 
of patients with newly-diagnosed rectal cancer patients (n = 
20), metastatic NSCLC patients (n = 25) and healthy controls 
(n = 30). Statistics were performed using the Kruskal Wallis 
H test. (A) Applying flow cytometry no difference was found 
concerning CEC/CEP detection in the peripheral blood of 
cancer patients and healthy controls. (Note the logarithmic 
scale.) (B) In comparison to healthy controls gene expres-
sion of endothelial cell markers CD34 and KDR was signifi-
cantly elevated in patients with metastatic NSCLC but not in 
patients with newly-diagnosed localized rectal cancer 
patients. (* p < 0.05; bars indicate mean +/- SD).BMC Research Notes 2008, 1:71 http://www.biomedcentral.com/1756-0500/1/2
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from patients with a high tumor burden, i.e., metastatic
NSCLC, we found significantly elevated gene expression
levels of CD34 and KDR which may indicate an elevated
number of CEC. Importantly, these markers are not spe-
cific for endothelial cells and might as well reflect circulat-
ing hematopoietic progenitors due to tumor-associated
inflammatory stimuli, metastatic cells or platelet contam-
ination. This represents the major limitation of the qPCR
methodology as applied in our study: gene transcript
quantification is carried out on total RNA derived from
PBMNC. Thus and in contrast to flow cytometry, qPCR
does not allow to identify distinct cell types through
simultaneous assessment of multiple markers on one cell
and the detection of CD34 and KDR gene expression
alone in PBMNC is by no means proof for CEC/CEP. But
currently there are no specific CEC/CEP markers available,
crucial for a valid molecular detection assay. Enrichment
procedures (e.g., immunomagnetic beads for CD146) are
currently being studied to improve CEC detection limits
achievable with flow cytometry. However, it remains to be
determined whether these labor-intensive techniques can
provide the purity and cell numbers required for proper
flow cytometric CEC enumeration.
In conclusion qPCR is more sensitive, but less specific
than 4-channel flow cytometry for the detection of CEC/
CEP. Nevertheless, both methods failed to reliably detect
an increase of CEC/CEP in tumor patients. However,
despite significant improved detection limits by qPCR a
single marker expressed specifically in CEP/CEC is hith-
erto missing. Such a marker would be crucial to achieve
high specificity and to discriminate these rare cells from
other cell populations of the peripheral blood. Thus, tran-
scriptome analysis of sorted and functionally tested CEC/
CEP might lead to the discovery of novel markers that can
be used in real-time PCR-based assays.
Methods
Acquisition of blood samples
The study was carried out according to the regulations of
the local ethics committee and Austrian Law. After having
obtained informed consent, peripheral blood samples
were drawn from patients with newly diagnosed, locally
advanced rectal cancer (n = 20), metastatic non-small cell
lung cancer (NSCLC; n = 25) and from age-mached
healthy volunteers (n = 30). Women during the active
menstrual phase were excluded from the study. Patients'
characteristics are summarized in table 1.
Isolation of progenitor cells from cord blood
Human umbilical cord blood samples (n = 10) were
obtained at birth from full-term newborns. Blood samples
were collected in heparinized tubes and stored at 8°C no
longer than 12 h before flow cytometric analysis and
mRNA extraction, respectively. MNC were isolated by
Ficoll density gradient centrifugation (Lymphoprep®,
Nycomed, Norway). Progenitor cells were enriched by a
two step immunomagnetic bead separation protocol by
negative selection for CD45 and subsequent positive
selection for CD34+  (CD34 isolation kit, CD45
microbeads, Miltenyi Biotec). Progenitor cells were spiked
into PBMNC of healthy volunteers at frequencies ranging
from 0.001 to 1%.
Generation of endothelial colony forming cells (ECFC) 
from peripheral blood
Autologous ECFC cultures were generated as described
previously [7,13]. Briefly, PBMNC from five healthy
donors were isolated by Ficoll density gradient centrifuga-
tion, resuspended in EGM-2 medium (Cambrex) and
placed into a six-well-plate coated with type I collagen
(from kangaroo, Sigma-Aldrich). After 24 h, non-adher-
ent cells were removed by changing the medium. Autolo-
gous ECFC were spiked into PBMNC of the corresponding
donor at frequencies ranging from 0.001 to 1%.
Flow cytometry
Flow cytometric detection and enumeration of of CEC/
CEP was carried out according to a recently published pro-
tocol [14]. Except for the anti-CD34 antibody mono-
clonal antibodies were chosen exactly as suggested by the
authors. In brief, after Fc-blocking (Fc-receptor blocking
antibody, Miltenyi Biotec) PBMNC were incubated in
triplicates with antibodies specific for CD31-FITC (BD
Pharmingen), CD34-PC7 (Beckman Coulter), CD45
PerCP (BD Pharmingen), CD133-PE (Miltenyi Biotec) or
VEGF-R2 (KDR)-PE (R&D Systems). Appropriate fluoro-
chrome-conjugated isotype-matched murine IgG antibod-
ies (BD Pharmingen) were used as controls for each
staining procedure. After incubation for 30 min at 4°C,
cells were washed, resuspended in 300 mL PBS and ana-
lyzed in a Cytomics-FC-500 cytometer using the Cytomics
RXP-Software (Beckman Coulter; figure 2). CEC were
defined as CD31+/CD34+/CD45-/CD133- and CEP were
defined as CD31+/CD34+/CD133+/CD45-/low  cells. All
Table 1: Patient characteristics
Parameters No. of patients
Rectal cancer patients 20
UICC stage I 6 (30%)
UICC stage II 5 (25%)
UICC stage III 9 (45%)
median age (years) 64
female 6 (30%)
NSCLC patients 25
UICC stage IV 25 (100%)
median age (years) 65
female 10 (40%)BMC Research Notes 2008, 1:71 http://www.biomedcentral.com/1756-0500/1/2
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experiments were carried out in triplicates with analysis of
at least 5 × 105 cells per run.
Quantitative PCR
RNA was purified by cell lysis of 5 × 105 PBMNC and
nucleic acid extraction using of the RNeasy Kit (Qiagen).
Extracted total RNA was transcribed into cDNA with
oligo-dT- und hexanukleotide-random-primers and the
AMV-Reverse Transcriptase (all Promega). For qPCR anal-
ysis in the 20 ng of each cDNA were used in triplicates. 5
μL Sybr-green Mix (Bio-Rad), and 10 pMol of each primer
were mixed to the cDNA sample. Primer sequences and
PCR conditions are listed in table 2. Instead of determin-
ing the ubiquitously expressed CD31 gene we assessed
gene expression of the more specific endothelial marker
CD144. Analysis was carried out in a Bio-Rad iCycler
using the iCycler Software (Bio-Rad). Efficiency of the
used primer pairs was determined by logarithmic dilu-
tions of a highly concentrated cDNA template. Relative
quantification and statistical data analysis of triplicates
per sample was done according to the delta-Ct method
described by Pfaffl et al. [15].
External standards
For absolute quantification CD34, CD133, KDR and
CD144 cDNAs were subcloned by the use of the PCR-
Script cloning kit (Stratagene). Plasmid copies were calcu-
lated as follows: amount (copies/μL) = 6 × 1023 (copies/
mol) × concentration (g/μL)/MW (g/mol). Standard
curves were generated by logarithmic dilutions of tripli-
cates of the amplicon-containing plasmids in a complex
matrix of COS-7 cDNA. These external standard curves
were used to calculate copy numbers per μg total RNA in
all PBMNC samples using the iCycler software (BioRad).
Statistical analysis
Statistical analysis was performed with the GraphPad
Prism 5 software for Windows. All tests of statistical signif-
icance were two-sided. Student's t-test was used for the
analysis of spiking experiments. Kruskal Wallis H test was
applied to study differences between healthy controls, rec-
tal cancer patients and NSCLC patients.
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